These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36122348)

  • 61. Antitumor effect of nutrient synergy on human osteosarcoma cells U-2OS, MNNG-HOS and Ewing's sarcoma SK-ES.1.
    Roomi MW; Ivanov V; Kalinovsky T; Niedzwiecki A; Rath M
    Oncol Rep; 2005 Feb; 13(2):253-7. PubMed ID: 15643507
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment.
    Qiu Z; Hu J; Xu H; Wang W; Nie C; Wang X
    Anticancer Drugs; 2013 Aug; 24(7):677-89. PubMed ID: 23652276
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
    Alcantara MB; Dass CR
    J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome.
    Richichi B; Baldoneschi V; Burgalassi S; Fragai M; Vullo D; Akdemir A; Dragoni E; Louka A; Mamusa M; Monti D; Berti D; Novellino E; De Rosa G; Supuran CT; Nativi C
    Chemistry; 2016 Jan; 22(5):1714-21. PubMed ID: 26692423
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emetine exerts anticancer effects in U2OS human osteosarcoma cells via activation of p38 and inhibition of ERK, JNK, and β-catenin signaling pathways.
    Son J; Lee SY
    J Biochem Mol Toxicol; 2021 Oct; 35(10):e22868. PubMed ID: 34338395
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
    Tauro M; Shay G; Sansil SS; Laghezza A; Tortorella P; Neuger AM; Soliman H; Lynch CC
    Mol Cancer Ther; 2017 Mar; 16(3):494-505. PubMed ID: 28069877
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: an overview.
    Chaudhary AK; Pandya S; Ghosh K; Nadkarni A
    Mutat Res; 2013; 753(1):7-23. PubMed ID: 23370482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer.
    Rani V; Yadav D; Atale N
    Curr Pharm Des; 2021; 27(45):4557-4567. PubMed ID: 34459380
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structure-Activity Relationships of UTX-121 Derivatives for the Development of Novel Matrix Metalloproteinase-2/9 Inhibitors.
    Yamahana H; Komiya Y; Takino T; Endo Y; Yamada H; Asada C; Uto Y
    Chem Pharm Bull (Tokyo); 2021; 69(10):1017-1028. PubMed ID: 34602570
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
    Di Pizio A; Laghezza A; Tortorella P; Agamennone M
    ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
    Piperigkou Z; Manou D; Karamanou K; Theocharis AD
    Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking.
    Wang Y; Yang L; Hou J; Zou Q; Gao Q; Yao W; Yao Q; Zhang J
    J Biomol Struct Dyn; 2019 Feb; 37(3):649-670. PubMed ID: 29380672
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.
    Arkadash V; Yosef G; Shirian J; Cohen I; Horev Y; Grossman M; Sagi I; Radisky ES; Shifman JM; Papo N
    J Biol Chem; 2017 Feb; 292(8):3481-3495. PubMed ID: 28087697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pathological and therapeutic aspects of matrix metalloproteinases: Implications in osteosarcoma.
    Tang H; Tang Z; Jiang Y; Wei W; Lu J
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):218-224. PubMed ID: 31111666
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation.
    Kalva S; Agrawal N; Skelton AA; Saleena LM
    Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Selaginella tamariscina (Beauv.) possesses antimetastatic effects on human osteosarcoma cells by decreasing MMP-2 and MMP-9 secretions via p38 and Akt signaling pathways.
    Yang JS; Lin CW; Hsieh YS; Cheng HL; Lue KH; Yang SF; Lu KH
    Food Chem Toxicol; 2013 Sep; 59():801-7. PubMed ID: 23811101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management.
    Belal A; Elanany MA; Santali EY; Al-Karmalawy AA; Aboelez MO; Amin AH; Abdellattif MH; Mehany ABM; Elkady H
    Molecules; 2022 Jun; 27(11):. PubMed ID: 35684529
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography.
    Butsch V; Börgel F; Galla F; Schwegmann K; Hermann S; Schäfers M; Riemann B; Wünsch B; Wagner S
    J Med Chem; 2018 May; 61(9):4115-4134. PubMed ID: 29660282
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MMpI: A WideRange of Available Compounds of Matrix Metalloproteinase Inhibitors.
    Muvva C; Patra S; Venkatesan S
    PLoS One; 2016; 11(8):e0159321. PubMed ID: 27509041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.